Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
160
Employees160
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
160
Employees160

CAPR Key Statistics

Market cap
1.26B
Market cap1.26B
Price-Earnings ratio
-12.90
Price-Earnings ratio-12.90
Dividend yield
Dividend yield
Average volume
1.43M
Average volume1.43M
High today
$24.14
High today$24.14
Low today
$23.01
Low today$23.01
Open price
$24.02
Open price$24.02
Volume
1.25M
Volume1.25M
52 Week high
$40.37
52 Week high$40.37
52 Week low
$4.30
52 Week low$4.30

Stock Snapshot

Capricor(CAPR) stock is priced at $23.20, giving the company a market capitalization of 1.26B. It carries a P/E multiple of -12.90.

During the trading session on 2026-01-24, Capricor(CAPR) shares reached a daily high of $24.14 and a low of $23.01. At a current price of $23.20, the stock is +0.8% higher than the low and still -3.9% under the high.

Trading volume for Capricor(CAPR) stock has reached 1.25M, versus its average volume of 1.43M.

Over the past 52 weeks, Capricor(CAPR) stock has traded between a high of $40.37 and a low of $4.30.

Over the past 52 weeks, Capricor(CAPR) stock has traded between a high of $40.37 and a low of $4.30.

CAPR News

Simply Wall St 3d
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics?

Capricor Therapeutics recently reported that the FDA, after reviewing topline Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy, has issued a re...

Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics?

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.